TY - JOUR
T1 - ACE2 Protein Expression During Childhood, Adolescence, and Early Adulthood
AU - Schurink, Bernadette
AU - Roos, Eva
AU - Vos, Wim
AU - Breur, Marjolein
AU - van der Valk, Paul
AU - Bugiani, Marianna
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Amsterdam UMC Corona Research Funds (project number 2007794). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Funding Information:
We thank the Mortuary personnel of the Expert Centrum for Post-mortem Diagnostics of the Amsterdam UMC for their assistance during autopsies and O. Bugiani for critically revising the manuscript. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Amsterdam UMC Corona Research Funds (project number 2007794). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Publisher Copyright:
© 2022, Society for Pediatric Pathology All rights reserved.
PY - 2022/7
Y1 - 2022/7
N2 - Purpose and context. Angiotensin-converting enzyme 2 is the entry receptor for SARS-CoV and SARS-CoV-2. Variations in ACE2 expression might explain age-related symptomatology of COVID-19, that is, more gastro-intestinal symptoms and less pulmonary complaints. This study qualitatively investigated ACE2 protein expression in various organs from the fetal to the young adolescent stage. Method. Autopsy samples from lung, heart, liver, stomach, small intestine, pancreas, kidney, adrenals, and brain (when available) were obtained from twenty subjects aged 24 weeks gestational age through 28 years. Formalin-fixed paraffin-embedded 4-um-thick tissue sections were stained against ACE2. Key results. We showed that the extent of ACE2 expression is age-related. With age, expression increases in lungs and decreases in intestines. In the other examined organs, ACE2 protein expression did not change with age. In brain tissue, ACE2 was expressed in astrocytes and endothelial cells. Conclusions. Age-related ACE2 expression differences could be one substrate of the selective clinical vulnerability of the respiratory and gastro-intestinal system to SARS-CoV-2 infection during infancy.
AB - Purpose and context. Angiotensin-converting enzyme 2 is the entry receptor for SARS-CoV and SARS-CoV-2. Variations in ACE2 expression might explain age-related symptomatology of COVID-19, that is, more gastro-intestinal symptoms and less pulmonary complaints. This study qualitatively investigated ACE2 protein expression in various organs from the fetal to the young adolescent stage. Method. Autopsy samples from lung, heart, liver, stomach, small intestine, pancreas, kidney, adrenals, and brain (when available) were obtained from twenty subjects aged 24 weeks gestational age through 28 years. Formalin-fixed paraffin-embedded 4-um-thick tissue sections were stained against ACE2. Key results. We showed that the extent of ACE2 expression is age-related. With age, expression increases in lungs and decreases in intestines. In the other examined organs, ACE2 protein expression did not change with age. In brain tissue, ACE2 was expressed in astrocytes and endothelial cells. Conclusions. Age-related ACE2 expression differences could be one substrate of the selective clinical vulnerability of the respiratory and gastro-intestinal system to SARS-CoV-2 infection during infancy.
KW - ACE2
KW - SARS-CoV-2
KW - children
KW - immunohistochemistry
UR - http://www.scopus.com/inward/record.url?scp=85125898511&partnerID=8YFLogxK
U2 - 10.1177/10935266221075312
DO - 10.1177/10935266221075312
M3 - Article
C2 - 35220822
SN - 1093-5266
VL - 25
SP - 404
EP - 408
JO - Pediatric and Developmental Pathology
JF - Pediatric and Developmental Pathology
IS - 4
ER -